Patient group
Jugendliche im Alter zwischen 12 und < 18 Jahren mit chronischer Hepatitis C (Genotypen 1 und 4):
Added benefit not proven
Comparator
Ledipasvir/Sofosbuvir oder Glecaprevir/Pibrentasvir oder Sofosbuvir/Velpatasvir
final resolution2022-05-05active
Arzneimittel-Richtlinie/Anlage XII: Elbasvir/Grazoprevir (neues Anwendungsgebiet: chronische Hepatitis C, 12 bis < 18 Jahre)
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Structured conclusion
Final result by patient group
1 source-verified result
Decision orientation
What the G-BA did
4 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2022-05-05
- Effective
- 05.05.2022
- Action type
- final resolution
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
A listed target is not treated as a new directive version unless an official version source exists.
Official document package